UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
April 12, 2007
MedImmune, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-19131 |
|
52-1555759 |
|
(State or other jurisdiction of incorporation or organization) |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (301) 398-0000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On April 12, 2007, MedImmune, Inc. (the “Company”) issued a press release announcing that it was exploring possible strategic alternatives. A copy of the Company’s press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release by MedImmune, Inc., dated April 12, 2007. |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MedImmune, Inc. |
|||
|
|
|
|
|
|
|
Date: April 12, 2007 |
|
By: |
|
/s/ William C. Bertrand, Jr. Esq. |
|
|
|
|
|
William C. Bertrand Jr., Esq. |
|
|
|
|
|
Senior Vice President, General Counsel & |
3
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release by MedImmune, Inc., dated April 12, 2007. |
4